LivaNova PLC (LIVN)
NASDAQ: LIVNHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
LIVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.17B
- P/E (TTM)
- 22.46
- Forward P/E
- 16.21
- EPS (TTM)
- $3.38
- Dividend yield
- None
- 52-week range
- 48.82 – 85.76
- Day range
- 74.23 – 76.25
- Volume / Avg
- 467.18K / 645.31K
- Beta
- —
- Shares outstanding
- 54.93M
- Next earnings
- Nov 4, 2026
52-week range
LIVN stock today
Shares of LivaNova (LIVN) finished lower on Oct 8 at $75.91, a drop of 0.03% or $0.02 per share, versus the S&P 500's 0.47% decline. Shares are 11.5% below their 52-week high of $85.76, set on Aug 4, 2026 and 55.5% above the 52-week low of $48.82, in the middle of the past year's range. LIVN is up 23.4% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 42.2%.
At 22.5x trailing earnings, LivaNova trades in line with the peer-group median of 21.4x. Its forward P/E of 16.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. LivaNova's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About LivaNova
Company profileLivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Vladimir A. Makatsaria
- Headquarters
- Gloucester
- Employees
- 3,300
- Website
- livanova.com
Financial highlights
Full financialsIn fiscal 2025, LivaNova generated $1.39 billion in revenue, up 10.7% from fiscal 2024, its 3rd consecutive year of revenue growth. LivaNova reported a net loss of $242.5 million, compared with net income of $63.2 million a year earlier. Gross margin was 67.7% (down from 68.1%) and operating margin 14.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B |
| Growth | +10.74% | +8.66% | +12.89% | -1.31% | +10.82% |
| Net income | $-242.47M | $63.23M | $17.55M | $-86.25M | $-135.82M |
| EPS (diluted) | $-4.45 | $1.16 | $0.32 | $-1.61 | $-2.68 |
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$90.55+19.29%
- Strong buy 3
- Buy 6
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.90
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $1.93 vs —
LivaNova peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ITGRInteger Holdings Corporation | 126.65 | +0.05% | $4.31B | vs LIVN |
| TMDXTransMedics Group Inc. | 79.00 | -2.55% | $2.74B | vs LIVN |
| AXGNAxogen Inc. | 36.18 | +0.39% | $2.12B | vs LIVN |
| CNMDCONMED Corporation | 45.11 | +1.99% | $1.35B | vs LIVN |
| CBLLCeriBell Inc. | 23.15 | -1.41% | $888.45M | vs LIVN |
| INMDInMode Ltd. | 14.08 | +0.50% | $810.22M | vs LIVN |
| CVCapsoVision Inc. | 6.62 | +1.22% | $352.25M | vs LIVN |
| ELMDElectromed Inc. | 27.80 | -1.42% | $230.38M | vs LIVN |
Indexes, lists and sector
LivaNova stock FAQ
What is LivaNova's stock price today?
LIVN last traded at $75.91 as of Oct 8, 4:00 PM EDT, down 0.03% on the day. Prices are delayed at least 15 minutes.
When is LivaNova's next earnings date?
LivaNova is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.90.
What is LIVN's P/E ratio?
LIVN trades at a trailing P/E ratio of 22.46 and a forward P/E of 16.21, compared with a median of 21.4 for its closest peers.
Who is LivaNova's CEO?
Mr. Vladimir A. Makatsaria is the chief executive officer of LivaNova PLC, which has about 3,300 employees.
What is the LIVN 52-week high?
The 52-week high for LIVN is $85.76 and the 52-week low is $48.82. The stock is currently 11.5% below its high.